Zonisamide promotes survival of human-induced pluripotent stem cell-derived dopaminergic neurons in the striatum of female rats

Yoshifumi Miyawaki | Bumpei Samata | Tetsuhiro Kikuchi | Kaneyasu Nishimura | Jun Takahashi

Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan

Correspondence
Tetsuhiro Kikuchi and Jun Takahashi, Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo, Kyoto 606-8507, Japan. Email: tkikuchi@cira.kyoto-u.ac.jp (T.K.) and jbtaka@cira.kyoto-u.ac.jp (J.T.)

Present address
Kaneyasu Nishimura, Division of Integrated Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto, Japan

Funding information
This study was supported by a grant from the Network Program for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED)

Abstract
The transplantation of dopaminergic (DA) progenitors derived from pluripotent stem cells improves the behavior of Parkinson's disease model animals. However, the survival of DA progenitors is low, and the final yield of DA neurons is only approximately 0.3–2% the number of transplanted cells. Zonisamide (ZNS) increases the number of survived DA neurons upon the transplantation of mouse-induced pluripotent stem (iPS) cell-derived DA progenitors in the rat striatum. In this study, we induced DA progenitors from human iPS cells and transplanted them into the striatum of female rats with daily administration of ZNS. The number of survived DA neurons was evaluated 1 and 4 months after transplantation by immunohistochemistry, which revealed that the number of survived DA neurons was significantly increased with the administration of ZNS. To assess the mechanism of action of ZNS, we performed a gene expression analysis to compare the gene expression profiles in striatum treated with or without ZNS. The analysis revealed that the expression of SLIT-and NTRK-like protein 6 (SLITRK6) was upregulated in rat striatum treated with ZNS. In conclusion, ZNS promotes the survival of DA neurons after the transplantation of human-iPS cell-derived DA progenitors in the rat striatum. SLITRK6 is suggested to be involved in this supportive effect of ZNS by modulating the environment of the host brain.

KEYWORDS
dopaminergic neuron, induced pluripotent stem cell, Parkinson's disease, RRID:AB_2169021, RRID:AB_2190153, RRID:AB_2201528, RRID:AB_2244867, RRID:AB_2294104, RRID:AB_2340866, RRID:AB_2354074, RRID:AB_23534102, RRID:AB_2534105, RRID:AB_2535795, RRID:AB_2535864, RRID:AB_2556542, RRID:AB_2556546, RRID:AB_2556547, RRID:AB_2716768, RRID:AB_2801320, RRID:AB_390204, RRID:AB_442102, RRID:AB_477010, RRID:AB_90755, RRID:AB_94090, RRID:CVCL_RL23, RRID:RGD_1547866, RRID:RGD_9685748, RRID:SCR_001456, RRID:SCR_002798, RRID:SCR_010972, RRID:SCR_016264, RRID:SCR_017202, RRID:SCR_017205, RRID:SCR_017206, transplantation, Zonisamide
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by a loss of dopaminergic (DA) neurons in the substantia nigra. Major motor symptoms include tremors, muscular rigidity, akinesia, and postural reflex disturbance. Standard treatments for PD patients are drug administration and deep brain stimulation, but these treatments just relieve neurological symptoms and do not prevent the progressive degeneration of DA neurons.

As a more radical treatment, cell replacement of the lost DA neurons is being considered. The transplantation of fetal mesencephalic tissues has been performed since the 1980s and shows long-term improvement of the PD symptoms (Kefalopoulou et al., 2014; Li et al., 2016). However, fetal mesencephalic tissues are difficult to acquire, limiting the number of patients who can benefit from this therapy. Pluripotent stem cells (PSCs) are easier to access, which is why they are expected to become another cell source for the transplantation (Barker, Drouin-Ouellet, & Parmar, 2015). Another concern is that only a small fraction of grafted cells survive after transplantation, and the final yield of DA neuron is only about 0.3%–2% the number of the transplanted cells (Doi et al., 2014; Kikuchi et al., 2017). This result has important implications on the therapeutic benefit, because clinical trials using fetal mesencephalic tissues reported that the improvement of the clinical symptoms was related to the number of survived DA neurons in the striatum (Hagell & Brundin, 2001).

Zonisamide (ZNS) blocks calcium and sodium channels and is clinically used as an anticonvulsant. It also protects DA neurons from insults by neurotoxins such as rotenone and 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxy dopamine (Asanuma et al., 2010; Choudhury et al., 2010; Condello et al., 2013; Czapiński, Blaszczyk, & Czuczwar, 2005) and is used as a symptomatic treatment for PD patients (Uemura, Asano, Hikawa, Yamakado, & Takahashi, 2017). ZNS has been reported not only to have these direct effects on DA neurons, but also to have indirect effects that promote the production of neurotrophic factors by astrocytes (Asanuma et al., 2010). Although previous reports showed neuroprotective effects of ZNS in vivo (Asanuma et al., 2010; Choudhury et al., 2010, 2012) and in vitro (Kawajiri, Machida, Saiki, Sato, & Hattori, 2010), the mechanism of action remains elusive.

A previous study reported that the intraperitoneal administration of ZNS increased the number of survived mouse-induced pluripotent stem (iPS) cell-derived DA neurons in the rat striatum 1 month after transplantation (Yoshikawa, Samata, Ogura, Miyamoto, & Takahashi, 2013). However, it is not known if ZNS exerts the same effect on human DA neurons. To investigate the effect of ZNS on human DA neurons and its mechanism, we induced DA progenitors from human iPS cells and grafted them into the rat striatum accompanied by ZNS administration. Histological analyses revealed that ZNS increased the number of survived DA neurons at 1 and 4 months post transplantation. In addition, a microarray analysis and a co-culture experiment suggested that SLIT-and NTRK-like protein 6 (SLITRK6) plays a role in this effect.

### Significance

Cell transplantation therapy is expected to ameliorate the motor symptoms of Parkinson’s disease. The survival of transplanted cells, however, is low, and the final yield of dopaminergic (DA) neurons is only about 0.3%–2% the number of the transplanted cells. This low yield demands a large number of cells and potentially increases the safety risks of the cell therapy. Here we show that Zonisamide promotes the survival of transplanted human-induced pluripotent stem cell-derived DA neurons in rat brains. Further observation suggested that its mode of action was associated with the increased expression of SLIT-and NTRK-like protein 6 in the host striatum.
day starting 2 days before the transplantation until the day of euthanization. One or 4 months after the transplantation, the rats were euthanized with pentobarbital (Cat# 11441, Kyoritsu Seiyaku, Tokyo, Japan) administration and perfused with 4% paraformaldehyde (Cat# 30525-89-4, Wako). Brains were post fixed for 1 day with 4% paraformaldehyde and then transferred to 15% sucrose solution for one more day and then 30% sucrose solution until the day of sectioning at 4°C. The brains were sliced with a cryostat (CM-1850, Leica Biosystems, Wetzlar, Germany) at 30 µm thickness. A total of 60 rats were used in this study.

2.5 | Immunofluorescence studies

For in vitro studies, spheres and attached cells were fixed with 4% paraformaldehyde for 10 min. The spheres were sliced with a cryostat at 20 µm thickness and mounted on glass slides. The fixed cells were incubated with phosphate-buffered saline (PBS, Cat# 166-23555, Wako) containing 2% Triton X-100 (Cat# 9002-93-1, Sigma-Aldrich) for 30 min and blocked with PBS containing 4% BlockAce (Cat# UKB80, Megmilk Snow Brand, Tokyo, Japan) at room temperature for 10 min. The primary antibody reaction was performed overnight at 4°C. The antibodies used are listed in Supporting Information Table S1. After washing with PBS twice, the cells were incubated with PBS containing 4% BlockAce and Alexa Fluor-conjugated secondary antibodies at room temperature for 1 hr. After washing with PBS twice, the cells were incubated with PBS containing 4′,6-diamidino-2-phenylindole (DAPI, Cat# D1306, Dako) for nuclear staining and mounted on glass slides using Mowiol 4-88 (Cat# 81381, Sigma-Aldrich). The cells were visualized with a confocal laser microscope (Fluoview FV1200 D; Olympus, Tokyo, Japan, RRID:SCR_016264) or a fluorescence microscope (BZ X-710; Keyence, Osaka, Japan, RRID:SCR_017202). The number of TH⁺, NURR1⁺, FOXA2⁺, and K167⁺ cells was counted using 30-μm brain sections. One slice out of eight continuous sections was used for the cell count, and at least two sections per animal were counted. For human nuclei and SLITRK6, at least 300 cells in randomly selected 20× fields were counted.

2.6 | Microarray analysis

For microarray analysis, female F344 rats (CLEA Japan, Inc., Japan, RRID:RGD_1547866) were intraperitoneally injected with 60 mg kg⁻¹ day⁻¹ of ZNS (n = 4) or saline (vehicle control, n = 2) for seven successive days. Then the rats were euthanized, total RNA was extracted from the striatum using an RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA), and 100 ng of total RNA was used for the analysis. Samples were hybridized to GeneChip Rat Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's protocol. Arrays were scanned using the Microarray Scanner System (Agilent Technologies, Santa Clara, CA, USA, RRID:SCR_017206). The data were analyzed using GeneSpring GX13.1.1 software.
(Agilent Technologies, RRID:SCR_010972). The expression signals of the probe sets were calculated using RMA16. The microarray data are available from the Gene Expression Omnibus (GEO database, http://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE112624.

2.7 | Quantitative RT-PCR

Total RNA was extracted using an RNeasy Plus Mini Kit. The samples were reverse transcribed using the SuperScript III First-Strand Synthesis System (Cat#: 18080051, Invitrogen). Quantitative PCR reactions were carried out with a Power SYBR (Cat#: 4368577, Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. The expression level of each gene was normalized to that of GAPDH using the ΔΔCt method. The primers used are shown in Supporting information Table S2.

2.8 | Generation of HEK293T cells forcibly expressing SLITRK6 (SLITRK6-HEK293T cells)

A pPV-EF1a-SLITRK6iP-A vector was transfected into HEK293T cells by Lipofectamine 2000 reagent (Cat#: 12566014, Thermo Fisher Scientific, Waltham, MA, USA), and the cells were maintained in DMEM/F-12 Ham supplemented with l-glutamine and Phenol Red (Cat#: 12-719Q, Wako) supplemented with 10% fetal bovine serum (Cat#: 11550356, Sigma-Aldrich). After 24 hr, 2.5 µg/ml of puromycin (Cat#: 58-58-2, InvivoGen, San Diego, CA, USA) was added to the culture medium to select drug-resistant cells.

2.9 | Co-culture of SLITRK6-HEK293T cells and iPS cell-derived DA progenitors

Three days prior to co-culture, SLITRK6-HEK293T or HEK293T cells were dissociated into single cells with Accumax (Cat#: AM105, Innovative Cell Technologies, San Diego, CA, USA) and replated on poly-L-lysine-coated eight-well slide chamber plates at a density of 4.5 × 10^5 cells with Neurobasal Medium supplemented with B27 supplement and 2 mM l-glutamine. When we started the co-culture, attached Day-28 DA progenitors were dissociated into single cells with Accumax and replated on SLITRK6-HEK293T or HEK293T cultivated plates at a density of 1.5 × 10^3 cells. At Day 4 of the co-culture, the samples were fixed with 4% paraformaldehyde.

2.10 | Quantitation of fiber length

After immunostaining, TH+ fibers were measured by a BZ Analyzer II (Keyence, RRID:SCR_017205). Ten fibers per sample were randomly selected and measured, and the average value was considered the value for that sample.

2.11 | Oxidative stress test

At Day 28 of the culture, neurosphere media were changed to Neurobasal Medium minus phenol red (Cat#: 13248-017, Gibco) supplemented with B-27 Supplement Minus AO (Cat#: 10889038, Gibco) and 2 mM l-glutamine. ZNS was added at three different concentrations: 0.05, 0.5, and 5 µM. After 1 day of ZNS exposure, the cells were incubated with 1 mM H_2O_2 for 12 hr. The viability of the cells was examined with an LDH Cytotoxicity Detection Kit (Cat#: MK401, Takara Bio, Shiga, Japan) according to the manufacturer’s protocol.

2.12 | Maturation test

At Day 28 of the culture, neurosphere media were changed to Neurobasal Medium supplemented with B27 supplement and 2 mM l-glutamine. The cells were incubated with 10 or 100 µM ZNS for 14 days. At Day 42, the neurospheres were fixed with 4% paraformaldehyde and subjected to immunofluorescence staining.

2.13 | Statistical analysis

Statistical analyses were performed using a commercially available software package (GraphPad Prism, GraphPad Software, San Diego, CA, USA, RRID:SCR_002798). Differences were considered statistically significant when p < 0.05. Data from the analysis of brain slices 1 month after transplantation and neurospheres were analyzed by one-way ANOVA with the Bonferroni multiple comparison test (Figures 2b,d,e, 3b, and 4a,c). Data from the analysis of brain slices 4 months after transplantation, qPCR, and co-culture experiments were compared using an unpaired t test (Figures 2g,i–k, 3d, 5b, 6c, 8b–e). Data are shown as the mean ± standard deviation. n represents the number of independent experiments.

3 | RESULTS

3.1 | Differentiation of human iPS cells to DA progenitors

We induced DA progenitors from human iPS cells with the dual SMAD inhibition-based method (Chambers et al., 2009) (Figure 1a). On Day 12, we sorted Corin (a marker for floor plate) + cells to enrich DA progenitors (Doi et al., 2014). Immunostaining on Day 28 revealed that forkhead box protein A2 (FOX2, a marker for ventral cells) and nuclear receptor related 1 protein (NURR1, a marker for early midbrain DA neurons) + cells were 92.3 ± 2.1% and 48.3 ± 4.0% (n = 3), respectively (Figure 1b,c). With this method, most of the differentiated cells were LIM homeobox transcription factor 1 alpha (LMX1A, midbrain marker) + and FOXA2 + DA neuronal progenitors (Doi et al., 2014). The percentage of tyrosine hydroxylase
number of human nuclear antigen (HNA) + cells was 2.54 ± 1.56 × 10^5.

We transplanted Day-28 spheres into the rat striatum and administered saline (vehicle control) or ZNS (30 and 60 mg/kg).

### 3.2 | ZNS promoted survival of DA neurons 1 month after transplantation

We transplanted Day-28 spheres into the rat striatum and administered saline (vehicle control) or ZNS (30 and 60 mg/kg). Immunohistological analyses at 1 month revealed that the number of human nuclear antigen (HNA) + cells was 2.54 ± 1.56 × 10^5, and 3.08 ± 1.44 × 10^5 for the vehicle (n = 6), ZNS 30 mg/kg (n = 8) and 60 mg/kg (n = 8) groups, respectively (ANOVA [F(2, 19) = 0.349, p = 0.710]; Figure 2a,b). To assess the number of mature DA neurons, we performed double-labeled immunostaining for TH and NURR1 (Figure 2c). The number of TH+NURR1+ cells was significantly higher in the ZNS groups compared to the vehicle group (3.17 ± 1.64 × 10^5, 7.50 ± 1.95 × 10^5, and 8.16 ± 3.43 × 10^5 cells for vehicle, ZNS 30 and 60 mg/kg, respectively, ANOVA [F(2, 19) = 0.003]; Figure 2d). Similarly, the percentage of TH+NURR1+ cells among HNA+ cells was significantly higher in the ZNS groups (1.37 ± 0.59%, 2.53 ± 0.56%, and 2.84 ± 0.89% for vehicle, ZNS 30 mg/kg, and 60 mg/kg, respectively, ANOVA [F(2, 19) = 8.16 ± 3.43 × 10^5, p = 0.004]; post hoc Bonferroni multiple comparison test: vehicle versus. ZNS30, p = 0.016, vehicle versus ZNS60, p = 0.005; Figure 2e). Thus, ZNS administration increased the number of survived DA neurons in the rat striatum 1 month after transplantation.

### 3.3 | ZNS promoted survival of DA neurons 4 months after transplantation

From the above results, we continued observation of the ZNS 60 mg/kg group and examined the survival of DA neurons with or without ZNS (60 mg/kg) 4 months after transplantation. The number of survived HNA+ cells was significantly higher in the ZNS 60 mg/kg (n = 5) group compared to the vehicle (n = 6) group (8.80 ± 2.16 × 10^5 and 1.86 ± 0.74 × 10^5 cells for vehicle and ZNS 60 mg/kg groups, respectively, p = 0.012; Figure 2f,g). Again, the number of TH+NURR1+ cells was significantly higher in the ZNS 60 mg/kg group (6.64 ± 2.24 × 10^5 and 1.51 ± 0.65 × 10^5 cells for vehicle and ZNS 60 mg/kg, respectively, p = 0.015; Figure 2h,i). However, there was no significant difference in the percentage of TH+NURR1+ cells among HNA+ cells between the two groups (7.52 ± 1.99% and 8.37 ± 2.67% for vehicle and ZNS 60 mg/kg, respectively, p = 0.557; Figure 2j). Additionally, most of the HNA+ cells were FOXA2+ (91.3 ± 2.6% and 90.1 ± 5.1% for vehicle and ZNS 60 mg/kg, respectively, p = 0.624; Figure 2k).

Thus, at 4 months, ZNS administration promoted the survival of the grafted cells including DA neurons.

### 3.4 | ZNS did not promote proliferation of DA progenitors

We examined whether the increase of survived DA neurons was a result of promoted DA progenitor proliferation. We assessed cell proliferation by quantifying the percentage of Ki67+ cells among FOXA2+ cells. At 1 month, there was no significant difference in proliferating midbrain DA progenitors among the vehicle and ZNS groups (3.21 ± 1.89%, 2.05 ± 0.73%, and 2.07 ± 0.52% for vehicle (n = 6), ZNS 30 mg/kg (n = 8) and 60 mg/kg (n = 8), respectively,
ANOVA ($F(2, 19) = 2.345, p = 0.123$); Figure 3a,b). At 4 months after transplantation, the proliferating DA progenitors were much fewer, and there was no significant difference between the groups (0.21 ± 0.29% and 0.07 ± 0.10% for vehicle ($n = 6$) and ZNS 60 mg/kg ($n = 5$), respectively, $p = 0.332$; Figure 3c,d). Therefore, we concluded that ZNS does not promote the proliferation of midbrain DA progenitors.
FIGURE 3  Zonisamide (ZNS) does not promote proliferation of DA progenitors. (a) Immunofluorescence images of grafted cells 1 month after transplantation for FOXA2 (green), KI67 (red), and DAPI (blue). Scale bar = 50 µm. (b) Quantitation of KI67+ cells among FOXA2+ cells 1 month after transplantation. Saline (vehicle control, n = 6), ZNS 30 mg/kg (n = 8), and ZNS 60 mg/kg (n = 8). (c) Immunofluorescence images of grafted cells 4 months after transplantation for FOXA2 (green), KI67 (red), and DAPI (blue). Scale bar = 50 µm. (d) Quantitation of KI67+ cells among FOXA2+ cells 4 months after transplantation. Saline (n = 6) and ZNS (n = 5).

FIGURE 4  A Zonisamide (ZNS) direct effect was not observed by maturation or oxidative stress test. (a) Immunofluorescence images of sections of neurospheres at Day 42 (after 14 days exposure to ZNS). TH (green), FOXA2 (red), and DAPI (blue). Scale bar = 50 µm. (b) Quantitation of TH+NURR1+ cells of the 42-day culture. Control (n = 3), ZNS 10 µM (n = 3) and ZNS 100 µM (n = 3). (c) Culture supernatants were collected and analyzed for LDH activity 12 hr after adding H$_2$O$_2$. H$_2$O$_2$ (n = 4), ZNS 0 µM (n = 4), ZNS 0.05 µM (n = 4), ZNS 0.5 µM (n = 4), and ZNS 5 µM (n = 4).
3.5 | ZNS promotes the expression of SLITRK6 in rat striatum

To determine the mechanism for how ZNS supports the survival of DA neurons, we first examined the direct effect of ZNS on DA progenitors. We cultured Day-28 spheres with or without ZNS for another 14 days, but found no increase of TH+NURR1+ cells in the ZNS groups (ANOVA [F(2, 6) = 0.127, p = 0.883], Figure 4a,b). Then we examined if ZNS rescues DA progenitors from oxidative stress.

We quantified cell death in Day-28 spheres in the presence of H₂O₂ for 12 hr, but did not find any supportive effect of ZNS (ANOVA [F(4, 15) = 2.475, p = 0.089]; Figure 4c). These results suggested that any direct effect on DA neurons by ZNS is not likely the main mechanism that supports cell survival.

Next, in order to assess the indirect effect of ZNS, we performed a microarray analysis of the intact rat striatum with or without ZNS administration. A comparison between these two groups disclosed 26 genes that were upregulated in the ZNS group more than 1.5
times compared to the vehicle group (Figure 5a). After combining synonymous genes using RefSeq and Gene Symbol, 13 genes remained as candidates. Among them, 12 genes were identified to encode membrane or secreted proteins. We examined the expression of the 12 genes by quantitative RT-PCR and found that SLITRK6 was significantly upregulated in the ZNS group (n = 4) compared to the vehicle group (n = 4) (p = 0.031; Figure 5b). To determine what kind of cells express SLITRK6, we performed an immunofluorescence study of the intact rat striatum with or without ZNS administration for one successive month. SLITRK6 was expressed in choline acetyltransferase (CHAT, a marker for cholinergic neurons)\(^*\) cells, but not in DARPP-32 (a marker for striatal medium spiny neurons)\(^*\) or glial fibrillary acidic protein (GFAP, a marker for astrocytes)\(^*\) cells (Figure 6a). There was a significant difference in the number of SLITRK6\(^*\) cells in the striatum between the vehicle (n = 6) and the ZNS groups (n = 7) (3.30 ± 0.80 \(\times\) 10\(^3\) and 5.98 ± 1.62 \(\times\) 10\(^3\) cells/cm\(^2\) for vehicle and ZNS 60 mg/kg, respectively, p = 0.004; Figure 6b,c).

### 3.6 | SLITRK6 supports survival of DA neurons in vitro

To assess the effects of SLITRK6 on DA neurons, we generated SLITRK6-HEK293T cells (Figure 7). We dissociated Day-28 spheres, plated them onto SLITRK6-HEK293T cells and then performed an immunofluorescence study after 4 days (Figure 8a). The number of FOXA2\(^*\) cells was significantly higher in the SLITRK6 group (n = 4) compared to the control group (n = 4) (8.54 ± 0.48 \(\times\) 10\(^4\) and 5.86 ± 1.52 \(\times\) 10\(^4\) cells/cm\(^2\), respectively, p = 0.019; Figure 8b). Similarly, the number of TH\(^*\)NURR1\(^*\) cells was significantly higher in the SLITRK6 group compared to the control group (7.62 ± 1.77 \(\times\) 10\(^3\) and 4.51 ± 1.17 \(\times\) 10\(^3\) cells/cm\(^2\), respectively, p = 0.008; Figure 8c). In contrast, there was no significant difference in the percentage of TH\(^*\)NURR1\(^*\) cells among FOXA2\(^*\) cells between the two groups (8.89 ± 1.89% and 7.72 ± 0.93%, respectively, p = 0.308; Figure 8d). These results suggested that SLITRK6 supports the survival and/or proliferation.
of FOXA2+ DA progenitors, thereby increasing the number of TH+NURR1+ DA neurons. We also assessed the length of TH+ fibers in both conditions (n = 5, each). The average fiber length was significantly longer in the SLITRK6 group compared to the control group (1.01 ± 0.45 × 10^{−2} and 5.81 ± 1.86 × 10 μm, respectively, p = 0.024; Figure 8e).

4 | DISCUSSION

Our results show that the administration of ZNS increased the number of survived DA neurons after the transplantation of human-iPS cell-derived DA progenitors into rat striatum. We found that 4% of DA progenitors were proliferating at the time of injection. One month after the transplantation, the number of mature DA neurons (TH+NURR1+) in the graft had increased by ZNS, but the number of total survived cells (HNA+) had not. However, the number of proliferating KI67+ cells slightly decreased in ZNS-treated rats. These findings suggested that ZNS promoted the maturation of grafted DA progenitors. At 4 months, however, the number of HNA+ cells was higher in ZNS-treated rats, and there was no difference in the percentage of TH+NURR1+ cells among HNA+ cells. These results suggest that ZNS supports the survival and/or proliferation of DA progenitors/neurons over longer periods.

Previous reports suggested two potential mechanisms for the neuroprotective effects of ZNS: direct (Condello et al., 2013; Kawajiri et al., 2010) and indirect (Asanuma et al., 2010; Choudhury et al., 2010). In this study, we did not observe direct effects on DA progenitors (Figure 4). Therefore, we focused on the effect of ZNS on the host brain, finding by a microarray analysis that ZNS increased the expression of SLITRK6 in the rat striatum (Figure 5). SLITRK family proteins are single-pass transmembrane proteins that resemble SLIT in the outer-membrane portion and NTRK in the inner-membrane portion (Tekin et al., 2013). The SLITRK family consists of six proteins, SLITRK1–6, which are reported to bind to leukocyte common antigen-related receptor protein tyrosine phosphatases (LAR-RPTPs), which are synaptic adhesion molecules related to synapse development. Although the binding regions of SLITRKs and LAR-RPTP have been identified, the regions are not conserved in SLITRK6. SLITRK6 is expressed in the thalamus of mouse and zebrafish (Beaubien & Cloutier, 2009; Round, Ross, Angel, Shields, & Lom, 2014) and also in the human putamen (Aruga, Yokota, & Mikoshiba, 2003), but its target is not known (Um et al., 2014; Um & Ko, 2013). SLITRK6 is reported to facilitate synapse formation,
support the survival of neural cells, and control axonal extension, although its effects on neurite extension are controversial (Aruga et al., 2003; Katayama et al., 2009; Tekin et al., 2013).

We confirmed that CHAT+ cholinergic interneurons express SLITRK6 in the rat striatum. Cholinergic interneurons consist of about 1% of all neurons in the striatum (Lim, Kang, & McGehee, 2014). They extend neurites to the whole striatum and form synapses with the axons of DA neurons in the substantia nigra (Round et al., 2014). They also show synchronous excitation in response to input from thalamostriatal axons, which are positive for nicotinic acetylcholine receptors, thereby controlling DA release from DA neurons in the substantia nigra (Threlfell et al., 2012). We showed that co-culture with SLITRK6-HEK293T cells increased the survival of DA progenitors and consequently TH+NURR1+ DA neurons. In addition, the length of TH+ neurites became longer on SLITRK6-HEK293T cells. These findings suggest that SLITRK6 protein expressed on the surface of cholinergic neurons directly acts on the grafted cells.

One important limitation of this study is the small sample size, which may reduce the reproducibility and generalizability of our findings. Especially, the small sample size underpowered our in vitro analysis, in which we could not detect the direct effect of ZNS. Nevertheless, we confirmed the upregulation of SLITRK6 in the striatum of ZNS-treated rats by quantitative RT-PCR and immunohistology. Another limitation is that we only used female rats in this study. The survival rate of DA neurons significantly differs between genders when neurotoxin 6-hydroxydopamine was administered (Murray et al., 2003). That study suggested estrogen may have a neuroprotective effect, which could explain the difference. Because we used only female animals in this study, future experiments should investigate male rats.

Zonisamide promoted the survival of DA neurons after the transplantation of human-iPS cell-derived DA progenitors in rat striatum. This supportive effect of ZNS is suggested to be caused by the increased expression of SLITRK6 in the host striatum. ZNS is already available in the clinic and is expected to be useful for future PD cell therapy.

The authors, reviewers and editors affirm that in accordance to the policies set by the Journal of Neuroscience Research, this manuscript presents an accurate and transparent account of the study being reported and that all critical details describing the methods and results are present.

We thank Dr. K. Okita for providing the iPS cell line, Dr. A. Hotta for providing the pPV-EF1a-SLITRK6iP-A vector, Mr. K. Kubota for supporting the animal experiments, Dr. P. Karagiannis for reading of the manuscript and Sumitomo Dainippon Pharma Co., Ltd. for supplying zonisamide.

J.T. has a financial conflict of interest concerning this study, as below. Joint research funds: Sumitomo Dainippon Pharma Co., Ltd.
AUTHOR CONTRIBUTIONS
All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Conceptualization, Y.M. and J.T.; Methodology, Y.M.; Investigation, Y.M., B.S., and K.N.; Formal Analysis, Y.M.; Resources: Y.M., B.S., and K.N.; Writing – Original Draft, Y.M. and J.T.; Writing – Review & Editing, Y.M., T.K., and J.T.; Visualization, Y.M.; Supervision, J.T.; Funding Acquisition, J.T.

DATA AVAILABILITY STATEMENT
The microarray data are available from the Gene Expression Omnibus (GEO database, http://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE112624.

REFERENCES
Aruga, J., Yokota, N., & Mikoshiba, K. (2003). Human SLITRK family genes: Genomic organization and expression profiling in normal brain and brain tumor tissue. Gene, 315, 87–94. https://doi.org/10.1016/S0378-1119(03)00715-7
Asanuma, M., Miyazaki, I., Díaz-Corrales, F. J., Kimoto, N., Kikkawa, Y., Takeshima, M., ... Murata, M. (2010). Neuroprotective effects of zonismamide target astrocyte. Annals of Neurology, 67(2), 239–249. https://doi.org/10.1002/ana.21885
Barker, R. A., Drouin-Ouellet, J., & Parmar, M. (2015). Cell-based therapies for Parkinson disease—Past insights and future potential. Nature Reviews Neurology, 11(9), 492–503. https://doi.org/10.1038/nrneurol.2015.123
Beaubien, F., & Cloutier, J.-F. (2009). Differential expression of Slitrk family members in the mouse nervous system. Developmental Dynamics: An Official Publication of the American Association of Anatomists, 238(12), 3285–3296. https://doi.org/10.1002/dvdy.22160
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology, 27(3), 275–280. https://doi.org/10.1038/nbt.1529
Choudhury, M. E., Moritoyo, T., Yabe, H., Nishikawa, N., Nagai, M., Kubo, M., ... Nomoto, M. (2010). Zonismamide attenuates MPTP neurotoxicity in marmosets. Journal of Pharmacological Sciences, 114(3), 298–303. https://doi.org/10.1254/jfps.10120F
Choudhury, M. E., Sugimoto, K., Kubo, M., Iwaki, H., Tsujii, T., Kyaw, W. T., ... Nomoto, M. (2012). Zonismamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors. European Journal of Pharmacology, 689(1–3), 72–80. https://doi.org/10.1016/j.ejphar.2012.05.012
Condello, S., Currò, M., Ferlazzo, N., Costa, G., Visalli, G., Caccamo, D., ... Pisani, F. (2013). Protective effects of zonismamide against rotenone-induced neurotoxicity. Neurochemical Research, 38(12), 2631–2639. https://doi.org/10.1007/s11064-013-1181-2
Czapiński, P., Blaszczyk, B., & Czuczwar, S. J. (2005). Mechanisms of action of antiepileptic drugs. Current Topics in Medicinal Chemistry, 5, 3–14. https://doi.org/10.2174/156802605386962
Doi, D., Samata, B., Katsukawa, M., Kikuchi, T., Morizane, A., Ono, Y., ... Takahashi, J. (2014). Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports, 2(3), 337–350. https://doi.org/10.1016/j.stemcr.2014.01.013
Hagell, P., & Brundin, P. (2001). Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. Journal of Neuropathology and Experimental Neurology, 60(8), 741–752. https://doi.org/10.1093/jnen/60.8.741
Katayama, K.-I., Zine, A., Ota, M., Matsumoto, Y., Inoue, T., Fritzsch, B., & Aruga, J. (2009). Disorganized innervation and neuronal loss in the inner ear of Slitrk6-deficient mice. PLoS One, 4(11), 12. https://doi.org/10.1371/journal.pone.0007786
Kawajiri, S., Machida, Y., Saiki, S., Sato, S., & Hattori, N. (2010). Zonismamide reduces cell death in SH-SYSY cells via an anti-apoptotic effect and by upregulating MnSOD. Neuroscience Letters, 481(2), 88–91. https://doi.org/10.1016/j.neulet.2010.06.058
Kefalopoulou, Z., Politis, M., Piccini, P., Mencacci, N., Bhatia, K., Jahanshahi, M., ... Foltynie, T. (2014). Long-term clinical outcome of fetal cell transplantation for parkinson disease: Two case reports. JAMA Neurology, 71(1), 83–87. https://doi.org/10.1001/jamaneurol.2013.4749
Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., ... Takahashi, J. (2017). Human iPSC cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature, 548(7669), 592–596. https://doi.org/10.1038/nature23664
Li, W., Englund, E., Widner, H., Mattsson, B., van Westen, D., Ljtt, J., ... Li, J.-Y. (2016). Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating Parkinsonian brain. Proceedings of the National Academy of Sciences of the United States of America, 113(23), 6544–6549. https://doi.org/10.1073/pnas.1605245113
Lim, S. A. O., Kang, U. J., & McGehee, D. S. (2014). Striatal cholinergic interneuron regulation and circuit effects. Frontiers in Synthetic Neuroscience, 6, 22. https://doi.org/10.3389/fnsyn.2014.00022
Mashimo, T., Takizawa, A., Voigt, B., Yoshimi, K., Hiai, H., Kuramoto, T., & Serikawa, T. (2010). Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases. PLoS One, 5(1), e8870. https://doi.org/10.1371/journal.pone.0008870
Murray, H. E., Pillai, A. V., McArthur, S. R., Razvi, N., Datla, K. P., Dexter, D. T., & Gillies, G. E. (2003). Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostrial dopaminergic pathway of adult rats: Differential actions of estrogen in males and females. Neuroscience, 116, 213–222. https://doi.org/10.1016/s0306-4522(02)00578-x
Round, J., Ross, B., Angel, M., Shields, K., & Lam, B. (2014). Slitrk gene duplication and expression in the developing zebrafish nervous system. Developmental Dynamics: An Official Publication of the American Association of Anatomists, 243(3), 339–349. https://doi.org/10.1002/dvdy.24076
Samata, B., Kikuchi, T., Miyawaki, Y., Morizane, A., Mashimo, T., Nakagawa, M., ... Takahashi, J. (2015). X-linked severe combined immunodeficiency (X-SCID) rats for xeno-transplantation and behavioral evaluation. Journal of Neuroscience Methods, 243(30), 68–77. https://doi.org/10.1016/j.jneumeth.2015.01.027
Tekin, M., Chioza, B. A., Matsumoto, Y., Diaz-Horta, O., Cross, H. E., Demir, D., ... Crosby, A. H. (2013). SLITRK6 mutations cause myopathy and deafness in humans and mice. Neuron, 75(1), 54–68. https://doi.org/10.1016/j.neuron.2012.04.038
Uemura, M. T., Asano, T., Hikawa, R., Yamakado, H., & Takahashi, R. (2017). Zonismamide inhibits monoamine oxidase and enhances motor performance and social activity. Neuroscience Research, 124, 25–32. https://doi.org/10.1016/j.neures.2017.05.008
Um, J. W., Kim, K. H., Park, B. S., Choi, Y., Kim, D., Kim, C. Y., ... Kim, H. M. (2014). Structural basis for LAR-RPTP/Slitrk complex-mediated synaptic adhesion. Nature Communications, 5(1), 5423. https://doi.org/10.1038/ncomms6423
Um, J. W., & Ko, J. (2013). LAR-RPTPs: Synaptic adhesion molecules that shape synapse development. *Trends in Cell Biology, 23*(10), 465–475. https://doi.org/10.1016/j.tcb.2013.07.004

Yoshikawa, T., Samata, B., Ogura, A., Miyamoto, S., & Takahashi, J. (2013). Systemic administration of valproic acid and zonisamide promotes differentiation of induced pluripotent stem cell-derived dopaminergic neurons. *Frontiers in Cellular Neuroscience, 7*, 11. https://doi.org/10.3389/fncel.2013.00011

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

Table S1. List of antibodies
Table S2. List of primers
Transparent Peer Review Report
Transparent Science Questionnaire for Authors

How to cite this article: Miyawaki Y, Samata B, Kikuchi T, Nishimura K, Takahashi J. Zonisamide promotes survival of human-induced pluripotent stem cell-derived dopaminergic neurons in the striatum of female rats. *J Neurosci Res.* 2020;98:1575–1587. https://doi.org/10.1002/jnr.24668